购买非处方短效β2-激动剂与哮喘相关健康结果：SABINA III 研究的事后分析。

IF 3.1 3区医学 Q1 PRIMARY HEALTH CARE

NPJ Primary Care Respiratory Medicine Pub Date : 2024-11-01 DOI:10.1038/s41533-024-00397-4

David Price, Maarten J H I Beekman, Walter Javier Mattarucco, Rocio Martina Barriga-Acevedo, Hao-Chien Wang, Dina V Diaz, Adel Khattab, Manuel Pacheco Gallego, Ashraf Al Zaabi, Hisham Farouk, Darush Attar-Zadeh

{"title":"购买非处方短效β2-激动剂与哮喘相关健康结果：SABINA III 研究的事后分析。","authors":"David Price, Maarten J H I Beekman, Walter Javier Mattarucco, Rocio Martina Barriga-Acevedo, Hao-Chien Wang, Dina V Diaz, Adel Khattab, Manuel Pacheco Gallego, Ashraf Al Zaabi, Hisham Farouk, Darush Attar-Zadeh","doi":"10.1038/s41533-024-00397-4","DOIUrl":null,"url":null,"abstract":"This post-hoc analysis of the SABINA III study evaluated the association of short-acting β2-agonist (SABA) prescriptions and self-reported over-the-counter (OTC) SABA purchase in the previous 12 months with asthma-related outcomes using multivariable regression models in 4556 patients (mean age, 48.9 years). Of the 2810 patients prescribed ≥3 SABA canisters, 776 (27.6%) also purchased ≥1 SABA OTC. This subset of 776 patients reported the highest disease burden; 73.2% had ≥1 severe exacerbation and 55.7% had uncontrolled asthma. Asthma-related outcomes worsened with any SABA OTC purchase, regardless of SABA prescriptions; disease burden was the highest in patients with ≥3 SABA prescriptions and ≥1 SABA OTC purchase vs 1-2 SABA prescriptions only (86% lower odds of having at least partly controlled asthma and 124% increased incidence of severe asthma (both P < 0.001). These findings emphasize the need to implement policy changes to restrict SABA purchase without prescriptions and ensure access to affordable asthma care.","PeriodicalId":19470,"journal":{"name":"NPJ Primary Care Respiratory Medicine","volume":"34 1","pages":"34"},"PeriodicalIF":3.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530521/pdf/","citationCount":"0","resultStr":"{\"title\":\"Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study.\",\"authors\":\"David Price, Maarten J H I Beekman, Walter Javier Mattarucco, Rocio Martina Barriga-Acevedo, Hao-Chien Wang, Dina V Diaz, Adel Khattab, Manuel Pacheco Gallego, Ashraf Al Zaabi, Hisham Farouk, Darush Attar-Zadeh\",\"doi\":\"10.1038/s41533-024-00397-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This post-hoc analysis of the SABINA III study evaluated the association of short-acting β2-agonist (SABA) prescriptions and self-reported over-the-counter (OTC) SABA purchase in the previous 12 months with asthma-related outcomes using multivariable regression models in 4556 patients (mean age, 48.9 years). Of the 2810 patients prescribed ≥3 SABA canisters, 776 (27.6%) also purchased ≥1 SABA OTC. This subset of 776 patients reported the highest disease burden; 73.2% had ≥1 severe exacerbation and 55.7% had uncontrolled asthma. Asthma-related outcomes worsened with any SABA OTC purchase, regardless of SABA prescriptions; disease burden was the highest in patients with ≥3 SABA prescriptions and ≥1 SABA OTC purchase vs 1-2 SABA prescriptions only (86% lower odds of having at least partly controlled asthma and 124% increased incidence of severe asthma (both P < 0.001). These findings emphasize the need to implement policy changes to restrict SABA purchase without prescriptions and ensure access to affordable asthma care.\",\"PeriodicalId\":19470,\"journal\":{\"name\":\"NPJ Primary Care Respiratory Medicine\",\"volume\":\"34 1\",\"pages\":\"34\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11530521/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Primary Care Respiratory Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41533-024-00397-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PRIMARY HEALTH CARE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Primary Care Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41533-024-00397-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PRIMARY HEALTH CARE","Score":null,"Total":0}

引用次数: 0

摘要

这项 SABINA III 研究的事后分析采用多变量回归模型评估了 4556 名患者（平均年龄 48.9 岁）的短效 β2-受体激动剂 (SABA) 处方和自我报告的过去 12 个月内购买非处方 (OTC) SABA 与哮喘相关结果的关系。在处方量≥3 罐 SABA 的 2810 名患者中，有 776 人（27.6%）还购买了≥1 罐 SABA 非处方药。这 776 名患者中，73.2% 的患者≥1 次严重恶化，55.7% 的患者哮喘未得到控制。购买任何 SABA OTC 后，哮喘相关结果都会恶化，与 SABA 处方无关；与仅购买 1-2 个 SABA 处方的患者相比，购买≥3 个 SABA 处方和≥1 个 SABA OTC 的患者的疾病负担最重（至少部分控制哮喘的几率降低了 86%，严重哮喘的发生率增加了 124%（两者的 P

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Over-the-counter short-acting β₂-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study.

This post-hoc analysis of the SABINA III study evaluated the association of short-acting β₂-agonist (SABA) prescriptions and self-reported over-the-counter (OTC) SABA purchase in the previous 12 months with asthma-related outcomes using multivariable regression models in 4556 patients (mean age, 48.9 years). Of the 2810 patients prescribed ≥3 SABA canisters, 776 (27.6%) also purchased ≥1 SABA OTC. This subset of 776 patients reported the highest disease burden; 73.2% had ≥1 severe exacerbation and 55.7% had uncontrolled asthma. Asthma-related outcomes worsened with any SABA OTC purchase, regardless of SABA prescriptions; disease burden was the highest in patients with ≥3 SABA prescriptions and ≥1 SABA OTC purchase vs 1-2 SABA prescriptions only (86% lower odds of having at least partly controlled asthma and 124% increased incidence of severe asthma (both P < 0.001). These findings emphasize the need to implement policy changes to restrict SABA purchase without prescriptions and ensure access to affordable asthma care.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

NPJ Primary Care Respiratory Medicine PRIMARY HEALTH CARE-RESPIRATORY SYSTEM

CiteScore

5.50

自引率

6.50%

发文量

审稿时长

10 weeks

期刊介绍： npj Primary Care Respiratory Medicine is an open access, online-only, multidisciplinary journal dedicated to publishing high-quality research in all areas of the primary care management of respiratory and respiratory-related allergic diseases. Papers published by the journal represent important advances of significance to specialists within the fields of primary care and respiratory medicine. We are particularly interested in receiving papers in relation to the following aspects of respiratory medicine, respiratory-related allergic diseases and tobacco control: epidemiology prevention clinical care service delivery and organisation of healthcare (including implementation science) global health.